{
    "organizations": [],
    "uuid": "0410326f92dad71ad29da631f6c2b50957df26b3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cidara-says-additional-data-confir/brief-cidara-says-additional-data-confirm-positive-results-in-antifungal-rezafungin-idUSASC09T5C",
    "ord_in_thread": 0,
    "title": "BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 11 PM / Updated 8 minutes ago BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin Reuters Staff March 21 (Reuters) - Cidara Therapeutics Inc: * CIDARA THERAPEUTICS PROVIDES CLINICAL DATA UPDATES FOR ITS LEAD ANTIFUNGAL REZAFUNGIN * CIDARA THERAPEUTICS - ADDITIONAL DATA AND ANALYSES FROM STRIVE PHASE 2 CLINICAL TRIAL CONFIRM POSITIVE EFFICACY RESULTS IN BOTH REZAFUNGIN ARMS Source text for Eikon: Further company coverage:",
    "published": "2018-03-21T14:09:00.000+02:00",
    "crawled": "2018-03-21T14:28:33.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "additional",
        "data",
        "confirm",
        "positive",
        "result",
        "antifungal",
        "rezafungin",
        "reuters",
        "staff",
        "march",
        "reuters",
        "cidara",
        "therapeutic",
        "inc",
        "cidara",
        "therapeutic",
        "provides",
        "clinical",
        "data",
        "update",
        "lead",
        "antifungal",
        "rezafungin",
        "cidara",
        "therapeutic",
        "additional",
        "data",
        "analysis",
        "strive",
        "phase",
        "clinical",
        "trial",
        "confirm",
        "positive",
        "efficacy",
        "result",
        "rezafungin",
        "arm",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}